Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pliant Therapeutics Inc (PLRX)

Pliant Therapeutics Inc (PLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 820,921
  • Shares Outstanding, K 60,854
  • Annual Sales, $ 1,580 K
  • Annual Income, $ -161,340 K
  • EBIT $ -222 M
  • EBITDA $ -225 M
  • 60-Month Beta 1.05
  • Price/Sales 513.79
  • Price/Cash Flow N/A
  • Price/Book 2.35

Options Overview Details

View History
  • Implied Volatility 117.58% ( +20.03%)
  • Historical Volatility 57.90%
  • IV Percentile 92%
  • IV Rank 56.20%
  • IV High 167.73% on 08/13/24
  • IV Low 53.23% on 12/27/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 316
  • Put/Call OI Ratio 3.89
  • Today's Open Interest 10,330
  • Open Int (30-Day) 8,145

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.95
  • Number of Estimates 7
  • High Estimate -0.78
  • Low Estimate -1.02
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -37.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.53 +11.95%
on 12/23/24
15.80 -11.20%
on 12/03/24
+0.69 (+5.17%)
since 11/26/24
3-Month
10.22 +37.28%
on 10/02/24
16.10 -12.86%
on 11/06/24
+2.86 (+25.60%)
since 09/26/24
52-Week
10.22 +37.28%
on 10/02/24
19.62 -28.49%
on 01/08/24
-4.49 (-24.24%)
since 12/26/23

Most Recent Stories

More News
Pliant Therapeutics to Participate in Upcoming Investor Events

PLRX : 14.03 (+4.00%)
Pliant Therapeutics Presents Positive INTEGRIS-PSC Trial Data at The Liver Meeting® 2024

Pliant Therapeutics presented clinical data on bexotegrast, showing positive effects in primary sclerosing cholangitis at AASLD 2024.Quiver AI SummaryPliant Therapeutics, Inc. announced the presentation...

PLRX : 14.03 (+4.00%)
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

PLRX : 14.03 (+4.00%)
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

PLRX : 14.03 (+4.00%)
Pliant Therapeutics to Participate in the Stifel Healthcare Conference

PLRX : 14.03 (+4.00%)
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

PLRX : 14.03 (+4.00%)
Why Shares of Pliant Therapeutics Are Rising Tuesday

The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.

PLRX : 14.03 (+4.00%)
Why Pliant Therapeutics Stock Is Skyrocketing This Week

The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.

PLRX : 14.03 (+4.00%)
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

PLRX : 14.03 (+4.00%)
NVS : 98.40 (+0.05%)
CPRX : 21.91 (+1.34%)
NBIX : 139.03 (+1.83%)
Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development

PLRX : 14.03 (+4.00%)

Business Summary

Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO,...

See More

Key Turning Points

3rd Resistance Point 14.00
2nd Resistance Point 13.78
1st Resistance Point 13.63
Last Price 14.03
1st Support Level 13.26
2nd Support Level 13.04
3rd Support Level 12.89

See More

52-Week High 19.62
Fibonacci 61.8% 16.03
Fibonacci 50% 14.92
Last Price 14.03
Fibonacci 38.2% 13.81
52-Week Low 10.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar